Exosomes: Emerging Therapeutic Nanocarriers in Drug Delivery & Disease Diagnostics
DOI:
https://doi.org/10.22270/ajprd.v14i3.1773Abstract
Exosomes are naturally occurring extracellular vesicles with diameters ranging from approximately 30 to 150 nm, secreted by a wide variety of cell types. They serve as important mediators of intercellular communication by transporting bioactive molecules such as proteins, lipids, DNA, RNA, and other nucleic acids between cells. Owing to their inherent biocompatibility, structural stability, low immunogenicity, and ability to traverse biological barriers, including the blood–brain barrier, exosomes have emerged as highly promising nanocarriers for therapeutic and diagnostic applications. Unlike many synthetic delivery systems, such as liposomes and polymeric nanoparticles, exosomes exhibit enhanced resistance to metabolic degradation and possess natural targeting capabilities. Generated during various physiological and pathological processes, these vesicles have gained considerable interest in the field of precision medicine for their potential to address disease mechanisms at the molecular level. This review outlines the fundamental biology of exosomes, including their origin, classification, physicochemical characteristics, and cargo composition relevant to drug delivery. It further explores their therapeutic potential in areas such as cancer treatment, neurological diseases, and tissue regeneration. In addition, the application of exosome-based systems for the delivery of small-molecule drugs, proteins, and nucleic acids is discussed, along with an overview of leading organizations and research groups actively involved in the development and clinical evaluation of exosome-derived therapeutic platforms.
Downloads
References
Sen S, Xavier J, Kumar N, Ahmad M, Ranjan O, “Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives”, Biotech,2023, 13:101.
Doyle L, Wang M,“Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis”, Cells,2019, 8:727.
Kucuk N, Primozic M, Knez Z, Leitgeb M,“Exosomes engineering and their roles as therapy delivery tools, therapeutic targets, and biomarkers”,Int J Mol Sci. 2021, 22:43–95.
Kim H, Jang H, Cho H, “Recent advances in exosome-based drug delivery for cancer therapy”Cancers,2021, 13: 35–44.
Akuma P, Okagu O, Udenigwe C, “Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds”Front Sustain Food Syst,2019,3: 23.
Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P, “Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications”Int J Nanomed,2020, 15:6917–6934.
Daßler-Plenker J, Kuttner V, Egeblad M,“Communication in tiny packages: exosomes as means of tumor-stroma communication”Biochim Biophys Acta Rev Cancer,2020, 1834–1873.
Chen H, Wang L, Zeng X, “Exosomes, a new star for targeted delivery”Front Cell Dev Biol.,2021, 9:27, 28.
Liang Y, Duan L, Lu J, Xia J,“Engineering exosomes for targeted drug delivery. Theranostics,2021, 11:31–33.
Johnstone R, Adam M, Hammond J, Orr L, Turbide C,“Vesicle formation during reticulocyte maturation: Association of plasma membrane activities with released vesicles (exosomes)”J. Biol. Chem.,1987, 262:9412–9420.
Simons M, Raposo G, “Exosomes: vesicular carriers for intercellular communication”Curr. Opin. Cell Biol. 2009, 21:575–581.
Qin J, Xu Q, “Functions and application of exosomes” Acta Pol Pharm.,2014, 71:537–543.
Agrawal AK, Aqil F, Jeyabalan J,“Milk-derived exosomes for oral delivery of paclitaxel”Nanomed Nanotechnol. Biol. Med., 2017, 13:1627–1636.
Wu B, Sun D, Ma L, et al. Exosomes isolated from CAPS1-overexpressing colorectal cancer cells promote cell migration. Oncol Rep.,2019, 42:2528–2536.
Mu J, Zhuang X, Wang Q,“Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles” Mol Nutr Food Res.,2014, 58:1561–1573.
Ha D, Yang N, Nadithe V,“Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges”Acta Pharm Sin B.,2016,6:287–296.
Vlassov AV, Magdaleno S, Setterquist R, Conrad R, “Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials” Biochim Biophys Acta Gen Subj.,2012,18 (20):940–948.
Kalani A, Tyagi A, Tyagi N,“Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics”Mol Neurobiol.,2014,49:590–600.
Subra C, Laulagnier K, Perret B, Record M, “Exosome lipidomic unravels lipid sorting at the level of multivesicular bodies”Biochimie,2007, 89:205–212.
Liu W-z, Ma Z-j, Kang X-w, “Current status and outlook of advances in exosome isolation”Anal Bioanal Chem,2022, 414:7123–7141.
Yu L-L, Zhu J, Liu J-X, “A comparison of traditional and novel methods for the separation of exosomes from human samples”BioMed Res Int.,2018, 34–36.
Sidhom K, Obi P, Saleem A, “A review of exosomal isolation methods: is size exclusion chromatography the best option”Int J Mol Sci.,2020, 21:64–66.
Martins T, Vaz M, Henriques A,“A review on comparative studies addressing exosome isolation methods from body fluids”Anal Bioanal Chem.2023, 415: 1239–1263.
Shi J, Zhang Y, Yao B, “Role of exosomes in the progression, diagnosis, and treatment of gliomas”Med Sci Mon Int Med J Exp Clin Res: international medical journal of experimental and clinical research,2020, 26, 924021–924023.
Whiteside T,“Exosomes carrying immunoinhibitory proteins and their role in cancer” Clin Exp Immunol.,2017, 189:259–267.
Li S-p, Lin Z-x, Jiang X-y, Yu X-y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin.,2018, 39:542–551.
O’Brien K, Breyne K, Ughetto S, Laurent L, Breakefield X, “RNA delivery by extracellular vesicles in mammalian cells and its applications”Nat Rev Mol Cell Biol., 2020, 21:585–606.
Sarko D, McKinney C, “Exosomes: origins and therapeutic potential for neurodegenerative disease” Front Neurosci. 2017, 11:82.
Luarte A, B´atiz LF, Wyneken U, Lafourcade C,“Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche”Stem Cell Int., 2016, 59, 60.
Liu C, Su C, “Design strategies and application progress of therapeutic exosomes”Theranostics,2019, 9:10–15.
Hu Q, Su H, Li J, et al. Clinical applications of exosome membrane proteins. Precision Clinical Medicine,2020, 3:54–66.
Zhu L, Oh JM, Gangadaran P, “Targeting and therapy of glioblastoma in a mouse model using exosomes derived from natural killer cells”Front Immunol.,2018, 9.
Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into exosome transport through the blood–brain barrier and the potential therapeutical applications in brain diseases. Pharmaceuticals.,2023, 16:571.
Hao S-C, Ma H, Niu Z-F, Sun S-Y, Zou Y-R, Xia H-C,“hUC-MSCs secreted exosomes inhibit the glioma cell progression through PTENP1/miR-10a-5p/PTEN pathway”Eur Rev Med Pharmacol Sci.,2019, 23:10013–10023.
Liu C-G, Song J, Zhang Y-Q, Wang P-C. “MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA- 193b is a biomarker of Alzheimer’s disease”Mol Med Rep.,2014, 10:2395–2400.
Pusic AD, Pusic KM, Kraig RP,“What are exosomes and how can they be used in multiple sclerosis therapy”Expert Rev Neurother.,2014, 14:353–355.
Xin H, Li Y, Buller B, “Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth”Stem Cell., 2012, 30:1556–1564.
Zhang Z, Chopp M,“Exosomes in stroke pathogenesis and therapy”J. Clin. Invest., 2016, 126:1190–1197.
Xiong Y, Mahmood A, Chopp M,“Emerging potential of exosomes for treatment of traumatic brain injury”Neural Regener Res.,2017, 12–19.
Gutierrez-Millan C, Calvo Díaz C, Lanao J, Colino C,“Advances in exosomes-based drug delivery systems”Macromol Biosci.,2021, 21, 60–69.
Wang H, Sui H, Zheng Y, “Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway”Nanoscale.,2019, 11:7481–7496.
Yang X, Shi G, Guo J, Wang C, He Y, “Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus”Int. J. Nanomed., 2018, 13:80–95.
Graner M, Alzate O, Dechkovskaia A, “Proteomic and immunologic analyses of brain tumor exosomes”Faseb J., 2009, 23:15–41.
Cho E, Nam G-H, Hong Y, “Comparison of exosomes and ferritin protein nanocages for the delivery of membrane protein therapeutics”J. Contr. Release.,2018, 279:326–335.
Th´ery C, Zitvogel L, Amigorena S, “Exosomes: composition, biogenesis and function” Nat Rev Immunol.,2002, 2:569–579.
Qu M, Lin Q, Huang L, “Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease”J. Contr. Release,2018, 287:156–166.
Sun D, Zhuang X, Xiang X, “A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes”Mol Ther. 2010, 18:1606–1614.
Saari H, L´azaro-Ib´a˜nez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M, “Microvesicleand exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells”J. Contr. Release,2015, 220:727–737.
Tian Y, Li S, Song J,“A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy”Biomaterials,2014, 35: 2383–2390.
Lai R, Tan S, Teh B, “Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome”Int. J. Proteomic,2012, 907–971.
Kooijmans S, Aleza C, Roffler S, van-solinge W, Vader P,Schiffelers R,“Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting”J. Extracell Vesicles,2016, 5: 310–353.
Aspe J, Diaz Osterman C, Jutzy J, Deshields S, Whang S, Wall N,“Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant”J. Extracell Vesicles,2014, 3: 232–244.
Limoni S, Moghadam M, Moazzeni S, Gomari H, Salimi F,“Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells”Appl. Biochem. Biotechnol.,2019, 187:352–364.
Vinas J, Burger D, Zimpelmann J, “Transfer of microRNA-486-5p from human endothelial colony forming cell–derived exosomes reduce ischemic kidney injury” Kidney Int.,2016, 90:1238–1250.
Skog J, Wurdinger T, Van Rijn S, “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers”Nat Cell Biol., 2008, 10:1470–1476.
Alhasan A, Patel P, Choi C, Mirkin C,“Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents” Small,2014, 10: 186–192.
Peng H, Ji W, Zhao R, “Exosome: a significant nano-scale drug delivery carrier”J. Mater Chem. B., 2020, 8:7591–7608.
Gehrmann U, Hiltbrunner S, Georgoudaki A, Karlsson M, N-aslund T, Gabrielsson S, “Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosyl ceramide on exosomes” Cancer Res.,2013, 73:3865–3876.
Kobayashi M, Sawada K, Miyamoto M, “Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer”Biochem. Biophys. Res. Commun.,2020, 527:153–161.
Ye Y, Zhang X, Xie F, “An engineered exosome for delivering sgRNA: Cas9 ribonucleoprotein complex and genome editing in recipient cells”Biomater. Sci. 2020, 8:2966–2976.
Yin H, Yang J, Zhang Q, Wang H, Xu J, Zheng J, “iRGD as a tumor-penetrating peptide for cancer therapy”Mol Med Rep.,2017, 15:2925–2930.
Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H,“Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis”J. Contr. Release,2020, 318:1–15.
Ohno S, Takanashi M, Sudo K, “Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells”Mol. Ther., 2013, 21(1): 185–191.
Tian T, Zhang HX, He C, “Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy”Biomaterials. 2018, 150: 137–149.
Yu H, Sun T, An J,“Potential roles of exosomes in Parkinson’s disease: from pathogenesis, diagnosis, and treatment to prognosis.”Front Cell Dev Biol.,2020, 8:86.
Vilaca-faria H, Salgado A, Teixeira F, “Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson’s disease”Cells,2019, 8:118.
Yang J, Luo S, Zhang J, “Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease”Neurobiol. Dis.,2021, 148, 105–118.
Santos P, Almeida F, “Exosome-based vaccines: history, current state, and clinical trials”Front Immunol.,2021, 12, 511–565.
Cacciottolo M, Nice J, Li Y, “Exosome-based multivalent vaccine: achieving potent immunization, broadened reactivity, and strong T-cell responses with nanograms of proteins”Microbiol. Spectr.,2023, 11, 323–325.
Published
Versions
- 2026-06-19 (2)
- 2026-06-15 (1)
How to Cite
Issue
Section
Copyright (c) 2026 Sumit Dilare, Raj Baghel, Anil Kumar Yadav, Muskan Tomar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 